The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Durability of the effects after cessation of lamivudine for 47 patients with HBeAg-negative chronic hepatitis B
Author(s): 
Pages: 938-939,943
Year: Issue:  9
Journal: JOURNAL OF SHANDONG UNIVERSITY(HEALTH SCIENCES)

Keyword:  肝炎乙型慢性拉米夫定持久性疗效;
Abstract: 目的:研究HBeAg阴性慢性乙型肝炎(HBeAg阴性慢乙肝)停药后拉米夫定疗效的持久性及影响因素.方法:对47例使用拉米夫定总疗程≥24月、HBV-DNA阴转达18个月以上HBeAg阴性慢乙肝,分别于停药后进行肝脏生化学、HBV-DNA检测和随访观察.结果:停药后3、6、12、24和36个月累计复发率分别为25.5%、25.5%、41.8%、48.3%和54.8%.复发23例,在4、9和12个月的复发累计病例分别占复发病例的52.2%、65.2%和82.6%,复发最长的1例为39个月.停药时的年龄与拉米夫定停药后疗效持久性有关.结论:HBeAg阴性慢乙肝拉米夫定停药后疗效持久性较HBeAg阳性低,年龄轻者复发率低.
Related Articles
loading...